← board
CRL
distress 1/10 · well-funded / low risk$230.28+5%today-1% from 52w high
Revenue
$996M
Liquidity
$193M
Runway
—
Shares 1y
-2%
Price & events
+2.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+5.3%
1D
+0.5%
1W
+23.4%
1M
+37.3%
3M
+4.9%
6M
+37.1%
1Y
+4.5%
2Y
-41.9%
5Y
-7.8%
All
Overview
- Market Cap
- $11.09B
- Volume
- 94.40K
- 52 Week Range
- $146 – $234
- Total Shares
- 48.17M
- Float Shares
- 47.65M
- Short %
- 10.43%
- % Held by Insiders
- 0.64%
- % Held by Institutions
- 123.34%
- RVOL
- 0.11x
- Beta
- 1.40
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-02-25partnershipSigned definitive agreement to divest CDMO and Cell Solutions businesses to GI PartnersSEC 8-K
- January 13, 2026conferencedata presentationsecondaryJ.P. Morgan 44th Annual Healthcare Conference presentationSEC 8-K
- December 3, 2025 at approximately 10:00 a.m. Eastern timeconferencedata presentationsecondaryPresentation at Evercore 8th Annual Healthcare Conference discussing Q4 demand trends.SEC 8-K
- 2025-05-06partnershipCooperation agreement with Elliott Investment Management.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $231 (+0% upside) · 15 analysts
- 2026-07-20CLSAOutperform → Hold
- 2026-07-13MizuhoNeutral
- 2026-07-09Morgan StanleyOverweight
- 2026-06-17Morgan StanleyEqual-Weight → Overweight
- 2026-05-29CLSAHold → Outperform
- 2026-05-08BarclaysOverweight
Competitors
- none identified
Recent news
- 2026-07-23Charles River Laboratories stock hits 52-week high at $238.46 By Investing.com - Investing.com Canada
- 2026-07-23Charles River Labs stock reflects mixed outlook as guidance reset follows scrutiny on Cambodian supp - Ad-hoc-news.de
- 2026-07-22Charles River stock edges higher as guidance and drug development demand frame 2026 outlook - Ad-hoc-news.de
- 2026-07-22Price to sales forward of Charles River Laboratories International, Inc. – NYSE:CRL - TradingView
- 2026-07-21Charles River Labs stock steadies as investors weigh recent earnings trends and outsourcing demand - Ad-hoc-news.de
- 2026-07-20Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
- 2026-07-20Charles River Laboratories Earnings Preview: What to Expect - Yahoo Finance
- 2026-07-20CLSA downgrades Charles River Labs stock rating on valuation - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.